Tacrolimus - Selten PharmaAlternative Names: SPI-026
Latest Information Update: 21 Apr 2015
At a glance
- Originator Selten Pharma; Stanford University
- Developer Selten Pharma
- Class Lactones; Macrolides
- Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; T cell activation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Pulmonary arterial hypertension